| Phase 1/27 trials |
|
Phase 1/2
|
NCT07239596 |
Jan 2026 → Dec 2030 expected |
renal cell carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06859775 |
Apr 2025 → Oct 2026 expected |
— |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06589778 |
Sep 2024 → Apr 2026 overdue |
non-small cell lung carcinoma |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06427239 |
Jun 2024 → Jun 2027 expected |
malignant pancreatic neoplasm |
Fudan University |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06373133 |
May 2024 → Nov 2026 expected |
colorectal cancer |
West China Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05416775 |
Aug 2022 → Jun 2026 |
non-small cell lung carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT05444088 |
Aug 2022 → Jun 2026 |
hepatocellular carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 211 trials |
|
Phase 2
|
NCT07704645 |
Aug 2026 → Jun 2028 expected |
non-small cell lung carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07682272 |
Jul 2026 → Jul 2027 expected |
hepatocellular carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07503639 |
Apr 2026 → Apr 2028 expected |
colorectal cancer |
Fudan University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07266025 |
Jan 2026 → Jun 2030 expected |
gastric adenocarcinoma, gastroesophageal adenocarcinoma |
Shanghai Zhongshan Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07241767 |
Nov 2025 → Nov 2027 expected |
lung cancer |
Jiangsu HengRui Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07110571 |
Aug 2025 → Aug 2026 overdue |
gastric cancer, gastroesophageal cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07071714 |
Jul 2025 → Oct 2031 expected |
colorectal cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07028281 |
Jul 2025 → Dec 2028 expected |
cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06778031 |
Feb 2025 → Jun 2028 expected |
carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06465563 |
Jul 2024 → Dec 2026 expected |
biliary tract cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06247956 |
Mar 2024 → Dec 2025 overdue |
digestive system carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
| Phase 2/32 trials |
|
Phase 2/3
|
NCT07454720 |
Mar 2026 → Nov 2032 expected |
— |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2/3
|
NCT06335355 |
Mar 2024 → Oct 2028 expected |
non-small cell lung carcinoma |
Shanghai Shengdi Pharmaceutical Co., Ltd |
Not yet recruiting
|
No outcome recorded
|
| Phase 34 trials |
|
Phase 3
|
NCT07691762 |
Jul 2026 → Apr 2031 expected |
hepatocellular carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07229625 |
Jan 2026 → Dec 2029 expected |
biliary tract cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07170995 |
Oct 2025 → Dec 2030 expected |
non-small cell lung carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06618664 |
Oct 2024 → Sep 2026 expected |
hepatocellular carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|